Payment overview · 2025
General Payments
$445.59
26 reported records · 8 companies
Healthcare provider profile · identity verified
Christopher W Sorrels, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CUSHING, OK · NPI 1023085636
Verified facts
What the public records show
CMS Open Payments records show Christopher W Sorrels, M.D. received $445.59 in general payments during 2025 across 26 reported records.
Lilly USA, LLC accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.87 | 31.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.40 | 17.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.91 | 15.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.19 | 11.0% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $45.20 | 10.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.71 | 6.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.54 | 5.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.77 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $445.59 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $119.94 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.94 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.91 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.19 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.19 | 3 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $45.20 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.93 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 139 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
139 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 30 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 570 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 550 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 411 | 95 |
| Gabapentin | Gabapentin | 388 | 80 |
| Lisinopril | Lisinopril | 382 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 370 | 60 |
| Furosemide | Furosemide | 355 | 80 |
| Omeprazole | Omeprazole | 288 | 58 |
| Potassium Chloride | Potassium Chloride | 281 | 70 |
| Baclofen | Baclofen | 232 | 47 |
| Tramadol Hcl | Tramadol Hcl | 216 | 37 |
| Eliquis | Apixaban | 214 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 63 |
| Alprazolam | Alprazolam | 201 | 28 |
| Buspirone Hcl | Buspirone Hcl | 201 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 45 |
| Trazodone Hcl | Trazodone Hcl | 187 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 54 |
| Carvedilol | Carvedilol | 181 | 49 |
| Sertraline Hcl | Sertraline Hcl | 180 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 40 |
| Celecoxib | Celecoxib | 163 | 33 |
| Glimepiride | Glimepiride | 155 | 27 |
| Montelukast Sodium | Montelukast Sodium | 154 | 27 |
| Metformin Hcl | Metformin Hcl | 139 | 37 |
| Mounjaro | Tirzepatide | 139 | 21 |
| Diazepam | Diazepam | 135 | 26 |
| Simvastatin | Simvastatin | 135 | 30 |
| Losartan Potassium | Losartan Potassium | 134 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 28 |
| Ozempic | Semaglutide | 113 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 26 |
| Pregabalin | Pregabalin | 110 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 22 |
| Famotidine | Famotidine | 105 | 33 |
| Spironolactone | Spironolactone | 103 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 23 |
| Meloxicam | Meloxicam | 96 | 24 |
| Allopurinol | Allopurinol | 95 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 27 |
| Methylprednisolone | Methylprednisolone | 94 | 79 |
| Estradiol | Estradiol | 93 | 16 |
| Cefdinir | Cefdinir | 91 | 66 |
| Farxiga | Dapagliflozin Propanediol | 90 | 11 |
| Metformin Hcl Er | Metformin Hcl | 90 | 17 |
| Temazepam | Temazepam | 90 | 16 |
| Prednisone | Prednisone | 88 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 13 |
| Clonazepam | Clonazepam | 84 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 23 |
| Alendronate Sodium | Alendronate Sodium | 79 | 16 |
| Finasteride | Finasteride | 79 | 14 |
| Aripiprazole | Aripiprazole | 77 | 13 |
| Atenolol | Atenolol | 77 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 17 |
| Azithromycin | Azithromycin | 75 | 57 |
| Ezetimibe | Ezetimibe | 75 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 74 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 14 |
| Ondansetron Odt | Ondansetron | 65 | 22 |
| Donepezil Hcl | Donepezil Hcl | 64 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 25 |
| Xarelto | Rivaroxaban | 64 | 11 |
| Mupirocin | Mupirocin | 62 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 18 |
| Torsemide | Torsemide | 55 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 53 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 52 | suppressed |
| Cephalexin | Cephalexin | 50 | 34 |
| Promethazine Hcl | Promethazine Hcl | 50 | 15 |
| Bumetanide | Bumetanide | 47 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 11 |
| Ibuprofen | Ibuprofen | 44 | 14 |
| Topiramate | Topiramate | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 11 |
| Sucralfate | Sucralfate | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 27 |
| Fluconazole | Fluconazole | 39 | 24 |
| Glipizide | Glipizide | 39 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Naproxen | Naproxen | 38 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 14 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 30 | suppressed |
| Nystatin | Nystatin | 30 | 19 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 18 |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 17 |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Glyburide | Glyburide | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Tyrvaya | Varenicline Tartrate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $445.59 · 26 records | Lilly USA, LLC | ABRYSVO, Cologuard Collection Kit, JARDIANCE, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SKYCLARYS, UBRELVY, UZEDY, VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error